
Anatero 1mg tablet
Salt Composition: Anastrozole
Expiry Date: 01/2028
Inclusive of all taxes
1X10 tablets
About The Product
Breast Cancer
Anatero tablet, a drug used in cancer treatment, belongs to a class of medications known as aromatase inhibitors. This group of drugs is used to combat certain types of breast cancer in women. Aromatase inhibitors work by targeting an enzyme called aromatase, which is responsible for producing estrogen in the body. By reducing the amount of estrogen in the body, aromatase inhibitors reduce the growth of specific breast cancer cells by lowering the amount of estrogen they require to survive and grow.
Uses
Breast Cancer
Side Effects
The side effects of the Anatero tablet can include:
- Hot flashes
- Headaches
- Joint pain
- Decrease in sexual desire or libido.
- High blood pressure
- Increased cholesterol levels
- Increased risk of osteoporosis in some people.
It is important to discuss the risks and benefits of Anastrozole with your doctor before starting the treatment.
How To Use
- As a prescription drug, Anatero tablet is typically taken in oral tablet form and just once a day.
- It has a very long half-life and can take up to eight weeks to reach maximum effectiveness in the body.
- Common side effects of the tablet include joint pain, hot flashes, headaches, anxiety, depression, nausea, and weight gain.
- As a medication, anastrozole is highly effective at treating certain types of breast cancer.
- Studies have found that it can reduce the risk of recurrence of hormone receptor-positive early-stage breast cancer by up to 65 percent.
- It is also incredibly safe and well-tolerated when taken alone or combined with other cancer drugs.
How It Works
Anatero tablet dose has numerous potential benefits for both women and men. By blocking the production of hormones like estrogen and testosterone, an Anastrozole dose can reduce the risk of cancer, alleviate symptoms associated with conditions like PCOS and endometriosis, and help relieve the effects of menopause.
Anastrozole effects can also reduce the risk of osteoporosis and heart disease. While Anastrozole's effects may have potential risks, its potential to help people in many different ways makes it a valuable medication for an array of conditions.
Safety Advice
Missed Doses
- It is advisable not to miss any dose.
- In case you miss a dose of Anatero 1mg tablet consult your doctor soon.
- Missing the dose will impact the overall health of the patients.
- So, it is always advisable to follow the prescription of the doctor strictly.
FAQs
The drug works by inhibiting the activity of the aromatase enzyme, which is found in cancer cells, and promotes the conversion of androgen hormones into estrogen.
This may stop the production of estrogen and cause the growth of cancer cells to slow down.
Reference
- Kobayashi K, Okuno N, Arai G, Nakatsu H, Maniwa A, Kamiya N, Satoh T, Kikukawa H, Nasu Y, Uemura H, Nakashima T, Mikami K, Iinuma M, Tanabe K, Furukawa J, Kobayashi H.(2024). Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Jpn J Clin Oncol. 51(4):544-551.
- Madan R, Dahut WL. (2022) Abiraterone's efficacy confirmed; time to aim higher. Lancet Oncol. 16(2):119-21.
- Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. (2023). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16(2):152-60.
- Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. (2023). Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 68(4):570-7.
- Sidaway P. (2025). Urological cancer: abiraterone treatment improves overall survival in patients with mCRPC. Nat Rev Clin Oncol. Mar;12(3):128.
- Sun Y, Zou Q, Sun Z, Li C, Du C, Chen Z, Shan Y, Huang Y, Jin J, Ye ZQ, Xie L, Lin G, Feng Y, De Porre P, Liu W, Ye D. (2025). Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 404-11.
- Zhou ZR, Liu SX, Zhang TS, Xia J, Li B.(2024). Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention. 15(3): 1313-1320.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
